Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Target Price at $12.38

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has been assigned a consensus recommendation of “Buy” from the five analysts that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $12.38.

Several equities research analysts recently commented on CRVS shares. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th. Oppenheimer raised their price objective on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several institutional investors have recently bought and sold shares of CRVS. Alpine Global Management LLC bought a new position in shares of Corvus Pharmaceuticals during the 4th quarter worth approximately $62,000. Squarepoint Ops LLC raised its stake in Corvus Pharmaceuticals by 712.5% in the 4th quarter. Squarepoint Ops LLC now owns 98,144 shares of the company’s stock valued at $525,000 after acquiring an additional 86,064 shares during the period. Sphera Funds Management LTD. bought a new stake in shares of Corvus Pharmaceuticals in the fourth quarter valued at approximately $2,678,000. RTW Investments LP bought a new stake in Corvus Pharmaceuticals during the 4th quarter valued at $14,335,000. Finally, Man Group plc purchased a new stake in shares of Corvus Pharmaceuticals during the fourth quarter worth $73,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Trading Down 5.1 %

Shares of CRVS opened at $3.94 on Friday. The firm’s fifty day simple moving average is $5.08 and its two-hundred day simple moving average is $6.05. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The stock has a market capitalization of $253.17 million, a P/E ratio of -4.24 and a beta of 1.07.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.